HLS Therapeutics Inc. announced that Laura A. Brege was appointed to the HLS Board of Directors and will serve as a member of the company's Audit Committee. Ms. Brege replaces Daniel Tassé, who has accepted the position of CEO at DBV Technologies and is stepping down from the HLS Board to focus his time on his new role. Ms. Brege is Managing Director of Cervantes Life Science Partners, LLC. Prior to joining Cervantes Life Science Partners, Ms. Brege served as Chief Executive Officer and President of Nodality Inc.